BioSpace News Archive

Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that it initiated the Phase 2 portion of a planned Phase 2/3 trial of GBT021601 (GBT601), the company’s investigational next-generation sickle hemoglobin (HbS) polymerization inhibitor.

Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today participation and presentations at the following conferences: FASEB’s The Genome Engineering Conference: Cutting-Edge Research and Applications on June 29, 2022 at 5:30 p.m. WET/12:30 p.m. ET in Lisbon, Portugal.

Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced it has initiated screening of subjects for the ORCA-V1 Phase 2 clinical trial.

Zydus Pharmaceuticals ( USA ) Inc., a wholly owned subsidiary of Zydus Lifesciences Ltd. announced that it has joined a new coalition of diverse stakeholders to address drug shortages in the United States.

The global leader in the fight against blood cancers, The Leukemia & Lymphoma Society (LLS), announced the launch of its Pediatric Acute Leukemia (PedAL) Master Clinical Trial, an unprecedented international collaboration led by LLS designed to fundamentally change how children with acute leukemias are treated.

Tryp Therapeutics , Inc. (CSE: TRYP) (OTCQB: TRYPF) (“Tryp” or the “Company”), a clinical-stage biotechnology company focused on developing psilocybin-based compounds for diseases with unmet medical needs, announced today the filing of a new provisional patent for the use of psilocybin for the treatment of patients with Binge Eating disorder (BED).

M.S.Q. Ventures (“MSQ”) is pleased to announce that its client, BioLineRx Ltd. (“BioLineRx”) (NASDAQ/TASE: BLRX), has successfully entered into a co-development agreement with GenFleet Therapeutics, Inc. , an immuno-oncology focused biopharmaceutical company based in Shanghai, China , for the development of Motixafortide in pancreatic ductal adenocarcinoma (“PDAC”).

BioMech Health, a division of BioMech Holdings, LLC which provides clinically actionable solutions to improve health, quality of life and performance, announced that it has received the award for “Best Overall Biometric Solution” in the fifth annual AI Breakthrough Awards.

Receptor Life Sciences (RLS), a clinical-stage pharmaceutical company developing innovative therapies to address central nervous system disorders, announced that the first patient has been dosed in its Phase 1b/2a clinical safety, tolerability, and efficacy study evaluating RLS103 in adult patients with acute anxiety within social anxiety disorder (SAD).

TAE Life Sciences presented in vivo and in vitro boron delivery data using the company’s novel compounds at the 60th Particle Therapy Co-Operative Group Conference, occurring June 27 – July 2, 2022.